Rain Oncology IncChange company Symbol lookupSelect an option...RAIN Rain Oncology IncSCHL Scholastic CorpACST Acasti Pharma IncSTBX Starbox Group Holdings LtdANCFX American Funds Fundamental Investors® Class ADFS Discover Financial ServicesEJH E-Home Household Service Holdings LtdPYXS Pyxis Oncology IncFLGC Flora Growth CorpBAOS Baosheng Media Group Holdings LtdGo
Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Company Profile
Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- --
- Price/Book (MRQ)
- 2.70x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Avanish VellankiChmn.
- Robert DoebelePres.
- Richard Paul BryceExec.VP
- Nelson D. Cabatuan
- Franklin M. Berger
Address
- 8000 Jarvis Avenue, Suite 204
- Newark, CA 94560
- Phone: (510) 953-5559
- https://www.rainoncology.com/
Insider Trading
During the most recent quarter, 1M shares were bought in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.